MIRZIGDO
DEAD

Serial Number

90710090

Owner

Celgene Corporation

Attorney

Xiomara Triana

Filing Date

May 13, 2021

Add to watchlist:

No watchlists yet
View on USPTO

MIRZIGDO Trademark

Serial Number: 90710090

MIRZIGDO is a trademark filed by Celgene Corporation on May 13, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Celgene Corporation (842 trademarks)

7 Powder Horn Drive
Warren, NJ 07059

Entity Type: 03

Trademark Details

Filing Date

May 13, 2021

Registration Date

Not Registered

Published for Opposition

August 30, 2022

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Dec 1, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Dec 1, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 24, 2025 EXRA
SOU EXTENSION 5 GRANTED
Jul 23, 2025 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jul 23, 2025 AITU
SOU TEAS EXTENSION RECEIVED
Apr 9, 2025 EEXT
SOU EXTENSION 5 FILED
Apr 8, 2025 EXT5
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 23, 2024 EXRA
SOU EXTENSION 4 GRANTED
Oct 23, 2024 EX4G
SOU EXTENSION 4 FILED
Oct 23, 2024 EXT4
SOU TEAS EXTENSION RECEIVED
Oct 23, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 15, 2024 EXRA
SOU EXTENSION 3 GRANTED
Mar 14, 2024 EX3G
SOU EXTENSION 3 FILED
Mar 14, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Mar 14, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 13, 2023 EXRA
SOU EXTENSION 2 GRANTED
Oct 11, 2023 EX2G
SOU EXTENSION 2 FILED
Oct 11, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Oct 11, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 8, 2023 EXRA
SOU EXTENSION 1 GRANTED
Apr 6, 2023 EX1G
SOU EXTENSION 1 FILED
Apr 6, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 6, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 25, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 30, 2022 NPUB
PUBLISHED FOR OPPOSITION
Aug 30, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 10, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 28, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 28, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 28, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 28, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 28, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 18, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 18, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 18, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 20, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jan 20, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jan 20, 2022 CNRT
ASSIGNED TO EXAMINER
Jan 20, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 12, 2021 NWOS
NEW APPLICATION ENTERED
May 17, 2021 NWAP